The Pharma Data

MARCH 16, 2021

3,4 From Week 52-100, low rates of radiographic progression of joint damage were observed in patients receiving TREMFYA q4w (0.75) and TREMFYA q8w (0.46), which were both further numerically reduced from the results observed during Weeks 0-52 (1.06, q4w; 0.99, q8w).1,2 from Week 0-24 while receiving placebo, and 0.34

Medicine 52

Medicine Doctors Doctor Development 52

The Pharma Data

NOVEMBER 30, 2020

” Abbreviations used: CGRP – calcitonin gene-related peptide. We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. About Sosei Heptares.

Licensing 40

Licensing Licensing Production Development 40

The Pharma Data

APRIL 27, 2022

The Food and Drug Administration’s (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. 1-4 Low HER2 expression occurs in both HR-positive and HR-negative disease.

HR 52

HR Trials Protein Medicine 52

The Pharma Data

DECEMBER 9, 2020

The findings should “de-escalate” treatment for many postmenopausal women, said Shapiro, a professor and director of translational breast cancer research at Mount Sinai’s Icahn School of Medicine in New York City. “Our goal is to offer patients ‘precision medicine,’ ” he said.

Hormones 52

Hormones Trials Medicine Clinical Trials 52

Advarra

MARCH 10, 2023

To add even more complexity to this rare disease, there are different types : Hemoglobin SS Hemoglobin SC Hemoglobin SB+(beta) thalassemia Hemoglobin SB 0 (Beta-zero) thalassemia Currently, the only cure for SCD is accomplished through a bone marrow transplant.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Doctors 98

pharmaphorum

NOVEMBER 16, 2022

Dr Wykoff also said: “Maybe the most interesting finding, from an efficacy perspective, was the finding that, when looking at reductions in GA lesion growths over six-month periods – 0-6, 6-12, 12-18, and 18-24 month intervals – there appeared to be an increasing treatment effect of pegcetacoplan over time.

Genetics 105

Genetics Trials Clinical Trials Clinical Trials 105

Pfizer

SEPTEMBER 28, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 49 (0)6131 9084 1513 Media@biontech.de. 49 (0)6131 9084 1074 Investors@biontech.de. . Tue, 09/27/2022 - 16:15. 09.28.2022.

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

XTalks

NOVEMBER 7, 2022

Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. There are between 0 to 10 CTCs per mL of blood in early-stage cancers versus thousands of CTCs per mL of blood in conditions like metastatic carcinoma. Concentration of CTCs in Cancer Patients.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Delveinsight

JULY 23, 2020

DelveInsight estimated that around 73% of the FCS cases in the 7MM were mainly diagnosed between the age group 0-10 years; however, research says that the diagnosis of the FCS, where it runs in the family, it is advisable to test for the disease during the pregnancy. Therapeutic Options and Unmet Needs.

Marketing 61

Marketing Gene Therapy Genome Genomics 61

The Pharma Data

AUGUST 15, 2021

target genes associated with cellular proliferation, angiogenesis and tumor growth. Native Hawaiian or other Pacific Islander; 82% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 16% had an ECOG PS of 1, and 1.6% WELIREG is the first HIF-2? inhibitor therapy approved in the U.S. As an inhibitor of HIF-2?,

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52

WCG Clinical

SEPTEMBER 26, 2023

” Dr. MacDonald, with a solid foundation in family medicine and clinical trials administration, guides listeners through a grounded exploration of psychedelic substances. After graduating top of his class from the University of Minnesota Medical School, Dr. McDonald completed a family medicine residency program as chief resident.

Research 59

Research Drugs Trials Clinical Research 59

The Pharma Data

MARCH 28, 2022

The Effisayil™ 1 trial, recently published in The New England Journal of Medicine , showed significant clearance of skin pustules in patients with GPP flares within the first week after treatment with a single intravenous dose of spesolimab versus placebo. of patients had no visible pustules after the 12-week trial duration and 81.3%

Dermatology 52

Dermatology Trials Contract Manufacturing Medicine 52

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. Food and Drug Administration (FDA) has approved FoundationOne®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

The Pharma Data

JANUARY 9, 2021

(NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

The Pharma Data

JANUARY 11, 2021

The AGILE trial platform, which will be the first to test VIR-7832 in humans, uses adaptable protocols and statistical models to enable the evaluation of candidate medicines for COVID-19 treatment. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.

Antibody 40

Antibody Clinical Trials Clinical Trials Trials 40

pharmaphorum

AUGUST 21, 2020

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing.

DNA 59

DNA Gene Sequencing Genetics FDA Approval 59

The Pharma Data

AUGUST 3, 2021

. “As we look to the balance of the year, we are excited to be launching LUMAKRAS , a first-in-class lung cancer treatment, and advancing a robust pipeline of potential new medicines to meet the demands of patients around the world.” 4% Dividends Paid Per Share $ 1.76 $ 1.60 39.3% (25.8) 55.0% (4.1) pts Tax Rate 16.8% 13.6% (1.0)

Sales 52

Sales Production Antibody Development 52

The Pharma Data

JUNE 26, 2021

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pfizer

OCTOBER 19, 2022

are immunocompromised or are on a medicine that affects the immune system. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. 49 (0)6131 9084 1513 Media@biontech.de. . Medicines, Research.

Vaccination 40

Vaccination Vaccine Clinical Trials Clinical Trials 40

The Pharma Data

NOVEMBER 24, 2020

Results from the ILLUMINATE-A and ILLUMINATE-B studies demonstrate that Oxlumo addresses the underlying pathophysiology of PH1 in adults, children and infants, and we believe this newly approved medicine has the potential to change the course of this progressive disease,” said Akshay Vaishnaw, M.D., President of R&D at Alnylam.

FDA Approval 52

FDA Approval Production RNA Medicine 52

The Pharma Data

SEPTEMBER 15, 2020

Pfizer’s Rare Disease late-stage pipeline currently includes three gene therapy programs that, if successful, are expected to gain regulatory approval by the end of 2023, with an additional pipeline of 10 preclinical initiatives that are at various stages of maturity. Internal Medicine. Safety was consistent with published data.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

OCTOBER 26, 2020

The treatment induced HPV-specific T-cell responses and was associated with increased levels of immune cell infiltration in the tumors and expression of genes associated with activation of the immune system. months versus 0% and a PFS of 1.4 months in pts without liver metastases (n=23) versus 0% and PFS of 1.4

Vaccination 52

Vaccination Vaccine Trials Containment 52

The Pharma Data

MAY 13, 2021

The Yale Journal of Biology and Medicine. Preventive Medicine Reports. Experimental & Molecular Medicine. Journal of addiction medicine. DOI: 10.1016/ B978-0-12-800101-1.00008-9. . DOI: 10.1007/ s40279-015-0381-0. . Neuroendocrinology of obesity. Br Med Bull. 2014;109:73-82. DOI: 10.1093/bmb/ldu001. .

Insulin 52

Insulin Production Hormones Medicine 52

The Pharma Data

MARCH 16, 2021

Therefore, these findings further highlight the potential longer-term benefit this first-of-its-kind medicine can have for people of varying ages and levels of SMA disease severity.”. and 0%, respectively) and influenza (0.8% and 0%, respectively). Chief Medical Officer and Head of Global Product Development.

Protein 52

Protein Medicine Trials Clinical Trials 52

The Pharma Data

FEBRUARY 25, 2021

Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine. The publication of the data in the New England Journal of Medicine reinforces the value of Evrysdi as an important treatment option for SMA.”.

FDA Approval 52

FDA Approval Protein Medicine In-Vitro 52